NCT06634875
Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
Registry fields
- Overall status
- RECRUITING
- Conditions
- Colorectal Cancer Metastatic
- Study type
- INTERVENTIONAL
- Phase
- PHASE2
- Primary purpose
- TREATMENT
- Intervention type
- DRUG
- Interventions
- isunakinra
- Lead sponsor
- Buzzard Pharmaceuticals (INDUSTRY)
Cached at: 2026-10-24 01:14:35
Brief summary
This study will enroll patients with colorectal cancer that is locally advanced or metastatic. The tumor must be microsatellite stable (MSS), have a tumor mutational burden that is high (TMB-H) and be kras mutated. Patients must have been treated with available approved treatments already. In this study the investigators are testing a new type of immunotherapy, the potent IL-1 inhibitor isunakinra to be added to already approved immunotherapy (PD-1/PD-L1 inhibitor) in an attempt to get this treatment to work in this treatment resistant type of tumor.
Contact
Need a report or Korean medical writing based on this trial?
Sign in with Kakao to continue